Maravai Lifesciences Holdings (MRVI) EBT Margin (2020 - 2026)
Maravai Lifesciences Holdings (MRVI) recorded quarterly EBT Margin of 9.92% in Q1 2026, up 92.15% quarter-over-quarter from 126.36% in Q4 2025, and up 10255.0% on a YoY basis from N/an in Q1 2025.
Maravai Lifesciences Holdings (MRVI) EBT Margin (2020 - 2026) Analysis & Trends
Maravai Lifesciences Holdings' EBT Margin history runs 7 years deep, the most recent figure standing at 9.92% for Q1 2026.
- In Q1 2026, EBT Margin rose 10255.0% year-over-year to 9.92%; the TTM figure through Mar 2026 stood at 92.22% (up 2841.0% YoY), while the FY2025 annual figure was 126.5%, down 2562.0% from the prior year.
- EBT Margin was 9.92% for Q1 2026 at Maravai Lifesciences Holdings, up from 126.36% in the prior quarter.
- In the past five years, EBT Margin ranged from a high of 885.05% in Q4 2023 to a low of 249.39% in Q3 2024.
- Historically, EBT Margin has averaged 9.79% across 5 years, with a median of 30.04% in 2024.
- The sharpest annual moves came in 2023 and 2024: EBT Margin soared 83822 bps in 2023, then slumped 96651 bps in 2024.
- A 5-year view of EBT Margin shows it stood at 46.83% in 2022, then soared by 1790 bps to 885.05% in 2023, then slumped by 109 bps to 81.46% in 2024, then sank by 55 bps to 126.36% in 2025, then jumped by 92 bps to 9.92% in 2026.
- The last three EBT Margin figures came in at 9.92% (Q1 2026), 126.36% (Q4 2025), and 108.45% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 788,338.31 Bn | 788,338.28 Bn | - | - |
| 2 | Belite Bio | 56,560.00 Bn | 56,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,329.30 Bn | 17,329.30 Bn | - | - |
| 4 | Legend Biotech | 3,341.00 Bn | 3,340.71 Bn | 242.10 Mn | 6.40% |
| 5 | Akari Therapeutics | 1,727.91 Bn | 1,727.91 Bn | - | - |
| 6 | Evaxion A | 1,536.68 Bn | 1,536.67 Bn | - | - |
| 7 | Psyence Biomedical | 238.34 Bn | 238.33 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.42 Bn | 106.17 Bn | 2.59 Bn | 41.95% |
| 9 | Abivax | 95.45 Bn | 95.45 Bn | - | - |
| 10 | Maravai Lifesciences Holdings | 747.50 Mn | 739.10 Mn | 33.70 Mn | -9.92% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -9.92% |
| Dec 31, 2025 | -126.36% |
| Sep 30, 2025 | -108.45% |
| Jun 30, 2025 | -156.39% |
| Mar 31, 2025 | -112.47% |
| Dec 31, 2024 | -81.46% |
| Sep 30, 2024 | -249.39% |
| Jun 30, 2024 | -30.04% |
| Mar 31, 2024 | -34.92% |
| Dec 31, 2023 | 885.05% |
| Sep 30, 2023 | -30.75% |
| Jun 30, 2023 | -19.39% |
| Mar 31, 2023 | -5.72% |
| Dec 31, 2022 | 46.83% |
| Sep 30, 2022 | 59.48% |
| Jun 30, 2022 | 72.09% |
| Mar 31, 2022 | 68.30% |
| Dec 31, 2021 | 63.34% |
| Sep 30, 2021 | 73.74% |
| Jun 30, 2021 | 66.99% |